A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects

Hongjie Qian,1,2 Qian Chen,1,2 Liyu Liang,1,2 Yang Zou,1,2 Huahua Pu,1,2 Liang Xin,1,2 Rong Song,1,2 Tingting Li,1,2 Huijuan Zhu,1,2 Yu Wang,3 Guanghui Tian,4 Jingshan Shen,2,3 Hualiang Jiang,2,3 Chen Yu,1,2 Zhen Wang,2,3 Jingying Jia1,2 1Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai...

Full description

Bibliographic Details
Main Authors: Qian H, Chen Q, Liang L, Zou Y, Pu H, Xin L, Song R, Li T, Zhu H, Wang Y, Tian G, Shen J, Jiang H, Yu C, Wang Z, Jia J
Format: Article
Language:English
Published: Dove Medical Press 2021-07-01
Series:Drug Design, Development and Therapy
Subjects:
tpn171h
pde5 inhibitor
safety
pharmacokinetics
food effect
healthy subjects
Online Access:https://www.dovepress.com/a-phase-i-study-to-evaluate-the-safety-tolerability-and-pharmacokineti-peer-reviewed-fulltext-article-DDDT

Internet

https://www.dovepress.com/a-phase-i-study-to-evaluate-the-safety-tolerability-and-pharmacokineti-peer-reviewed-fulltext-article-DDDT

Similar Items